- Home
- SLGB vs ASRT Comparison
SLGB vs ASRT Comparison
Compare SLGB & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLGB | ASRT |
|---|---|---|
| Founded | 2017 | 1995 |
| Country | Hong Kong | United States |
| Employees | N/A | 30 |
| Industry | Integrated Freight & Logistics | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.2M | 75.1M |
| IPO Year | 2025 | 1997 |
Fundamental Metrics
Financial Performance| Metric | SLGB | ASRT |
|---|---|---|
| Price | $1.91 | $0.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 43.0K | ★ 684.5K |
| Earning Date | 12-23-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | $92,917,774.00 | ★ $137,354,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $65.13 | ★ N/A |
| Revenue Growth | N/A | ★ 9.22 |
| 52 Week Low | $1.74 | $0.51 |
| 52 Week High | $6.08 | $1.04 |
Technical Indicators
Market Signals| Indicator | SLGB | ASRT |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 52.85 |
| Support Level | N/A | $0.65 |
| Resistance Level | N/A | $0.79 |
| Average True Range (ATR) | 0.00 | 0.04 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 0.00 | 98.92 |
Price Performance
Historical ComparisonAbout SLGB Smart Logistics Global Limited Ordinary Shares
Smart Logistics Global Ltd is a contract logistics solution provider in the PRC focusing on industrial raw materials line-haul transportation business. the group focuses on the logistics digital ecosystem through innovation, digital analytics, and infrastructure establishment.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.